Case number 1:22-cv-01423
AbbVie Inc. et al v. Alkem Laboratories Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 28, 2024 | 245 | NOTICE OF SERVICE of Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc.'s Second Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-12) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 06/28/2024) (2) |
| Jun 27, 2024 | 244 | AFFIDAVIT of Service for Notice of Subpoena with Exhibits served on Crinetics Pharmaceuticals, Inc. on June 11, 2024, filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Grivner, Geoffrey) (Entered: 06/27/2024) (2) |
| Jun 24, 2024 | 243 | NOTICE OF SERVICE of Plaintiffs' First Supplemental Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-14) filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 06/24/2024) (3) |
| Jun 20, 2024 | 242 | SO ORDERED, granting 241 Stipulation and Order of Dismissal between Plaintiffs and Prinston Defendants. (*Party Zhejiang Huahai Pharmaceutical Co., Ltd., Prinston Pharmaceutical Inc. and Solco Healthcare US, LLC terminated). Signed by Judge Jennifer L. Hall on 6/20/2024. (ceg) (Entered: 06/20/2024) (4) |
| Jun 18, 2024 | 241 | STIPULATION of Dismissal (Between Plaintiffs and Prinston Defendants) by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 06/18/2024) (4) |
| Jun 17, 2024 | 240 | NOTICE OF SERVICE of (1) Plaintiffs' Notice of Rule 30(b)(6) Deposition of Defendants Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc., (2) Plaintiffs' Notice of Deposition of Rajesh Kankula, (3) Plaintiffs' Notice of Deposition of Srinivasa Rao Katari, and (4) Plaintiffs' Notice of Deposition of Prakash B Shetiya filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 06/17/2024) (5) |
| Jun 7, 2024 | 237 | ORAL ORDER: Having reviewed the Joint Letter (D.I. 235 ), it is ordered that the September 5, 2024 Markman hearing is CANCELLED and all claim construction deadlines are VACATED. Ordered by Judge Jennifer L. Hall on 6/7/2024. (ceg) (Entered: 06/07/2024) (0) |
| Jun 7, 2024 | 238 | SO ORDERED, re 236 Stipulation and Order to Extend Time for (1) Plaintiffs to serve their Initial Infringement Contentions concerning the '845 and '854 patents on the Prinston Defendants to July 3, 2024; and (2) Prinston Defendants to serve their Initial Invalidity Contentions concerning the '845 and '854 patents to July 31, 2024. Signed by Judge Jennifer L. Hall on 6/7/2024. (ceg) (Entered: 06/07/2024) (2) |
| Jun 7, 2024 | 239 | NOTICE of Subpoena to Dr. Scott R. Struthers by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc. (Grivner, Geoffrey) (Entered: 06/07/2024) (30) |
| Jun 6, 2024 | 236 | STIPULATION TO EXTEND TIME for: (1) Plaintiffs to serve their Initial Infringement Contentions concerning the '845 and '854 patents on the Prinston Defendants to July 3, 2024; and (2) Prinston Defendants to serve their Initial Invalidity Contentions concerning the '845 and '854 patents to July 31, 2024 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 06/06/2024) (2) |
| Jun 5, 2024 | 235 | Joint Letter to The Honorable Jennifer L. Hall from Jeremy A. Tigan regarding Claim Construction Deadlines and Hearing. (Tigan, Jeremy) Modified on 6/5/2024 (ceg). (Entered: 06/05/2024) (1) |
| May 30, 2024 | 234 | SO ORDERED, re 233 Stipulation and Order to Extend Time for (1) Plaintiffs to serve their Initial Infringement Contentions concerning the '845 patent and the '854 patent on Defendants Prinston to June 6, 2024; and (2) Defendants Prinston to serve its Initial Invalidity Contentions concerning the '845 and '854 patents to July 3, 2024. Signed by Judge Jennifer L. Hall on 5/30/2024. (ceg) (Entered: 05/30/2024) (2) |
| May 29, 2024 | 233 | STIPULATION TO EXTEND TIME for: (1) Plaintiffs to serve their Initial Infringement Contentions concerning the '845 and '854 patents on the Prinston Defendants to June 6, 2024; and (2) Prinston Defendants to serve their Initial Invalidity Contentions concerning the '845 and '854 patents to July 3, 2024 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 05/29/2024) (2) |
| May 23, 2024 | 231 | NOTICE OF SERVICE of Hetero's Identification of Claim Terms and Phrases for Construction for U.S. Patent Nos. 11,690,845 and 11,690,854 filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 05/23/2024) (2) |
| May 23, 2024 | 232 | SO ORDERED, re 230 Stipulation and Order to Extend Time for Plaintiffs and Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC to exchange lists of claim terms for construction for the '845 and '854 patents to May 29, 2024. Signed by Judge Jennifer L. Hall on 5/23/2024. (ceg) (Entered: 05/23/2024) (2) |
| May 22, 2024 | 230 | STIPULATION TO EXTEND TIME for Plaintiffs and Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC to exchange lists of claim terms for construction for the '845 and '854 patents to May 29, 2024 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 05/22/2024) (2) |
| May 16, 2024 | 228 | STIPULATION TO EXTEND TIME for (1) Plaintiffs to serve their Initial Infringement Contentions concerning U.S. Patent Nos. 11,690,845 ("the '845 patent") and 11,690,854 ("the '854 patent") on Defendant Prinston; and (2) for Defendant Prinston to serve its Initial Invalidity Contentions concerning the '845 and '854 patents - filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Taylor, Daniel) (Entered: 05/16/2024) (2) |
| May 16, 2024 | 229 | SO ORDERED, re 228 Stipulation and Order to Extend Time for (1) Plaintiffs to serve their Initial Infringement Contentions concerning the '845 patent and the '854 patent on Defendants Prinston to May 30, 2024; and (2) Prinston to serve its Initial Invalidity Contentions concerning the '845 and '854 patents to June 26, 2024. Signed by Judge Jennifer L. Hall on 5/16/2024. (ceg) (Entered: 05/16/2024) (2) |
| May 15, 2024 | 227 | NOTICE OF SERVICE of Hetero's Initial Invalidity Contentions for U.S. Patent Nos. 11,690,845 and 11,690,854 filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 05/15/2024) (2) |
| May 2, 2024 | 225 | STIPULATION TO EXTEND TIME for: (1) Plaintiffs to serve their Initial Infringement Contentions concerning U.S. Patent Nos. 11,690,845 ("the '845 patent") and 11,690,854 ("the '854 patent") on Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC (collectively, "Prinston") to May 16, 2024; and (2) Prinston to serve its Initial Invalidity Contentions concerning the '845 and '854 patents to June 12, 2024 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 05/02/2024) (2) |
| May 2, 2024 | 226 | SO ORDERED, re 225 Stipulation and Order to Extend Time for (1) Plaintiffs to serve their Initial Infringement Contentions concerning the '845 patent and the '854 patent on Defendants Prinston to May 16, 2024; and (2) Prinston to serve its Initial Invalidity Contentions concerning the '845 and '854 patents to June 12, 2024. Signed by Judge Jennifer L. Hall on 5/2/2024. (ceg) (Entered: 05/02/2024) (2) |
| Apr 26, 2024 | 224 | NOTICE OF SERVICE of Defendants Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc.'s Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-12) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 04/26/2024) (2) |
| Apr 18, 2024 | 222 | SO ORDERED, re 221 Stipulation and Order to Extend Time for: (1) Plaintiffs to serve their Initial Infringement Contentions concerning the '845 patent and the '854 patent on Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC is extended to May 2, 2024, and the deadline for Prinston to serve its Initial Invalidity Contentions concerning the '845 and '854 patents is extended to May 29, 2024. Signed by Judge Jennifer L. Hall on 4/18/2024. (ceg) (Entered: 04/18/2024) (2) |
| Apr 18, 2024 | 223 | NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions Against Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc. for U.S. Patent Nos. 11,690,845 and 11,690,854 filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/18/2024) (3) |
| Apr 17, 2024 | 221 | STIPULATION TO EXTEND TIME for: (1) Plaintiffs to serve their Initial Infringement Contentions concerning U.S. Patent Nos. 11,690,845 ("the '845 patent") and 11,690,854 ("the '854 patent") on Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC (collectively, "Prinston") to May 2, 2024; and (2) the deadline for Prinston to serve its Initial Invalidity Contentions concerning the '845 and '854 patents to May 29, 2024 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 04/17/2024) (2) |
| Apr 12, 2024 | 219 | ANSWER to Complaint (D.I. 1 in C.A. No. 24-152-JLH) by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) (Entered: 04/12/2024) (30) |
| Apr 12, 2024 | 220 | NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC's, (1) Initial Disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (2) Initial Disclosures concerning ESI pursuant to Paragraph 3 of the District of Delaware Default Standard for Discovery, regarding U.S. Patent Nos. 11,690,845 and 11,690,854 filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) (Entered: 04/12/2024) (2) |
| Apr 5, 2024 | 215 | NOTICE OF SERVICE of core technical documents bearing bates numbers HETERO-ORIL000001-HETERO-ORIL022946, HETERO-ORIL022947-HETERO-ORIL027598 filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 04/05/2024) (2) |
| Apr 5, 2024 | 216 | ANSWER to 206 Answer to Complaint, Counterclaim (Plaintiff's Answer to Hetero's Counterclaims), by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 4/5/2024 (ceg). (Entered: 04/05/2024) (10) |
| Apr 5, 2024 | 217 | NOTICE OF SERVICE of (1) Plaintiffs' Second Supplemental Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Hetero Defendants; (2) Plaintiffs' Second Supplemental Initial Disclosures to Hetero Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery; and (3) Plaintiffs' Second Supplemental Disclosures to Hetero Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/05/2024) (3) |
| Apr 5, 2024 | 218 | NOTICE OF SERVICE of (1) Plaintiffs' Second Supplemental Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Prinston Defendants; (2) Plaintiffs' Second Supplemental Initial Disclosures to Prinston Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery; and (3) Plaintiffs' Second Supplemental Disclosures to Prinston Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/05/2024) (3) |
| Apr 2, 2024 | 213 | SO ORDERED, re 209 Stipulation and Order of Dismissal regarding U.S. Patent Nos. 7,419,983, 10,537,572, 10,682,351, and 11,542,239 between Plaintiffs and Defendant Sun Pharmaceutical Industries Limited. Signed by Judge Jennifer L. Hall on 4/2/2024. (ceg) (Entered: 04/02/2024) (4) |
| Apr 2, 2024 | 214 | SO ORDERED, re 210 Stipulation and Order of Dismissal regarding U.S. Patent Nos. 11,690,845 and 11,690,854 between Plaintiffs and Defendant Sun Pharmaceutical Industries Limited. (*Party Sun Pharmaceutical Industries Limited terminated). Signed by Judge Jennifer L. Hall on 4/2/2024. (ceg) (Main Document 214 replaced on 4/2/2024) (ceg). (Entered: 04/02/2024) (4) |
| Apr 1, 2024 | 212 | SO ORDERED, re 211 Joint STIPULATION TO EXTEND TIME to ANSWER complaint and to EXTEND deadlines for disclosures and core technical document production to April 12, 2024. (*Reset Answer Deadlines: Prinston Pharmaceutical Inc. answer due 4/12/2024). Signed by Judge Jennifer L. Hall on 4/1/2024. (twk) (Entered: 04/01/2024) (2) |
| Mar 28, 2024 | 211 | Joint STIPULATION TO EXTEND TIME to ANSWER complaint and to EXTEND deadlines for disclosures and core technical document production to April 12, 2024 - filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Taylor, Daniel) (Entered: 03/28/2024) (2) |
| Mar 25, 2024 | 209 | STIPULATION of Dismissal regarding U.S. Patent Nos. 7,419,983, 10,537,572, 10,682,351, and 11,542,239 (between Plaintiffs and Defendant Sun Pharmaceutical Industries Limited), by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 3/26/2024 (ceg). (Entered: 03/25/2024) (4) |
| Mar 25, 2024 | 210 | STIPULATION of Dismissal regarding U.S. Patent Nos. 11,690,845 and 11,690,854 (between Plaintiffs and Defendant Sun Pharmaceutical Industries Limited), by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 3/26/2024 (ceg). (Entered: 03/25/2024) (4) |
| Mar 21, 2024 | 208 | SO ORDERED, re 207 Stipulation and Order Amending Case Schedule. (*Reset Deadlines for Claim Construction Briefing and Markman Hearing for the '845 and '854 patents: Claim Construction Chart due by 6/5/2024; Claim Construction Opening Brief due by 6/19/2024; Claim Construction Answering Brief due by 7/17/2024; Claim Construction Reply Brief due by 7/24/2024; Joint Claim Construction Brief due by 8/2/2024; A Markman Hearing is set for 9/5/2024 at 01:00 PM in Courtroom 6D before Judge Jennifer L. Hall --- see Order for details). Signed by Judge Jennifer L. Hall on 3/21/2024. (ceg) Modified on 3/21/2024 (ceg). (Entered: 03/21/2024) (4) |
| Mar 15, 2024 | 206 | ANSWER to Complaint (filed in 24-cv-151 - Consolidated on March 5, 2024), COUNTERCLAIM against AbbVie Inc. by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V.(Grivner, Geoffrey) (Entered: 03/15/2024) (30) |
| Mar 15, 2024 | 207 | STIPULATION and [Proposed] Order Amending Case Schedule, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 3/15/2024 (ceg). (Entered: 03/15/2024) (4) |
| Mar 13, 2024 | 201 | SO ORDERED, granting 198 Stipulation of Dismissal Regarding U.S. Patent Nos. 10,537,572, 10,682,351, and 11,542,239 between Plaintiffs and Zenara Defendants. Signed by Judge Jennifer L. Hall on 3/13/2024. (ceg) (Entered: 03/13/2024) (4) |
| Mar 13, 2024 | 202 | SO ORDERED, re 199 Stipulation of Dismissal Regarding U.S. Patent Nos. 11,690,845 and 11,690,854 between Plaintiffs and Zenara Defendants. (*Party Biophore India Pharmaceuticals Private Ltd. and Zenara Pharma Private Limited terminated). Signed by Judge Jennifer L. Hall on 3/13/2024. (ceg) (Entered: 03/13/2024) (4) |
| Mar 13, 2024 | 203 | SO ORDERED, re 200 Stipulation and Order to Extend Time for Sun Pharmaceutical Industries Limited to respond to the Complaint in C.A. 24-153-JLH to April 8, 2024. (*Reset Answer Deadlines: Sun Pharmaceutical Industries Limited answer due 4/8/2024). Signed by Judge Jennifer L. Hall on 3/13/2024. (ceg) (Entered: 03/13/2024) (2) |
| Mar 13, 2024 | 204 | STIPULATION TO EXTEND TIME for Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC to answer, move, or otherwise respond to the Complaint from March 15, 2024 to March 29, 2024 - filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Taylor, Daniel) (Entered: 03/13/2024) (2) |
| Mar 13, 2024 | 205 | SO ORDERED, re 204 Stipulation and Order to Extend Time for Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC to respond to the Complaint in C.A. 24-152-JLH to March 29, 2024. (*Reset Answer Deadlines: Prinston Pharmaceutical Inc. answer due 3/29/2024; Solco Healthcare US, LLC answer due 3/29/2024; Zhejiang Huahai Pharmaceutical Co., Ltd. answer due 3/29/2024). Signed by Judge Jennifer L. Hall on 3/13/2024. (ceg) (Entered: 03/13/2024) (2) |
| Mar 12, 2024 | 200 | STIPULATION TO EXTEND TIME for Sun Pharmaceutical Industries Limited to respond to the Complaint in C.A. 24-153-JLH to April 8, 2024 - filed by Sun Pharmaceutical Industries Limited. (Gaza, Anne) (Entered: 03/12/2024) (2) |
| Mar 11, 2024 | 198 | STIPULATION of Dismissal regarding U.S. Patent Nos. 10,537,572, 10,682,351, and 11,542,239 (between Plaintiffs and Zenara Defendants) by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 3/12/2024 (ceg). (Entered: 03/11/2024) (4) |
| Mar 11, 2024 | 199 | STIPULATION of Dismissal regarding U.S. Patent Nos. 11,690,845 and 11,690,854 (between Plaintiffs and Zenara Defendants) by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 3/12/2024 (ceg). (Entered: 03/11/2024) (4) |
| Mar 8, 2024 | 197 | SO ORDERED, re 196 Amended Claim Construction Chart and Order. The June 3, 2024 Markman Hearing is cancelled. Signed by Judge Jennifer L. Hall on 3/8/2024. (ceg) (Entered: 03/08/2024) (4) |
| Mar 7, 2024 | 196 | AMENDED Joint Claim Construction Chart and [Proposed] Order by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Attachments: # 1 Cover Letter to The Honorable Jennifer L. Hall) (Tigan, Jeremy) Modified on 3/7/2024 (ceg). (Entered: 03/07/2024) (0) |
| Mar 5, 2024 | 195 | SO ORDERED, re (7 in 1:24-cv-00153-JLH, 194 in 1:22-cv-01423-JLH, 7 in 1:24-cv-00154-JLH, 10 in 1:24-cv-00151-JLH, 10 in 1:24-cv-00152-JLH) Stipulation and Order regarding Consolidation for all purposes. Signed by Judge Jennifer L. Hall on 3/5/2024. Associated Cases: 1:22-cv-01423-JLH, 1:24-cv-00151-JLH, 1:24-cv-00152-JLH, 1:24-cv-00153-JLH, 1:24-cv-00154-JLH(ceg) (Entered: 03/05/2024) (8) |
| Mar 1, 2024 | 194 | STIPULATION and [Proposed] Order Regarding Consolidation by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Dellinger, Megan) (Entered: 03/01/2024) (8) |
| Feb 22, 2024 | 193 | SO ORDERED, re 192 Stipulation and Order to Defer Briefing on Issues of Indefiniteness. Signed by Judge Jennifer L. Hall on 2/22/2024. (ceg) (Main Document 193 replaced on 2/22/2024) (ceg). (Entered: 02/22/2024) (4) |
| Feb 21, 2024 | 192 | STIPULATION to Defer Briefing on Issues of Indefiniteness by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 02/21/2024) (4) |
| Feb 20, 2024 | 189 | JOINT CLAIM Construction Chart by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 2/21/2024 (ceg). (Entered: 02/20/2024) (9) |
| Feb 20, 2024 | 190 | EXHIBIT re 189 Claim Construction Chart by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2 (Part 1 of 5), # 3 Exhibit 2 (Part 2 of 5), # 4 Exhibit 2 (Part 3 of 5), # 5 Exhibit 2 (Part 4 of 5), # 6 Exhibit 2 (Part 5 of 5), # 7 Exhibit 3, # 8 Exhibit 4 (Part 1 of 6), # 9 Exhibit 4 (Part 2 of 6), # 10 Exhibit 4 (Part 3 of 6), # 11 Exhibit 4 (Part 4 of 6), # 12 Exhibit 4 (Part 5 of 6), # 13 Exhibit 4 (Part 6 of 6), # 14 Exhibit 5)(Tigan, Jeremy) (Entered: 02/20/2024) (0) |
| Feb 20, 2024 | 191 | EXHIBIT re 189 Claim Construction Chart, 190 Exhibit to a Document,, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Attachments: # 1 Exhibit 6 (Part 1 of 14), # 2 Exhibit 6 (Part 2 of 14), # 3 Exhibit 6 (Part 3 of 14), # 4 Exhibit 6 (Part 4 of 14), # 5 Exhibit 6 (Part 5 of 14), # 6 Exhibit 6 (Part 6 of 14), # 7 Exhibit 6 (Part 7 of 14), # 8 Exhibit 6 (Part 8 of 14), # 9 Exhibit 6 (Part 9 of 14), # 10 Exhibit 6 (Part 10 of 14), # 11 Exhibit 6 (Part 11 of 14), # 12 Exhibit 6 (Part 12 of 14), # 13 Exhibit 6 (Part 13 of 14), # 14 Exhibit 6 (Part 14 of 14), # 15 Exhibit 7)(Tigan, Jeremy) (Entered: 02/20/2024) (0) |
| Feb 16, 2024 | 188 | STIPULATION and [Proposed] Order to Extend Certain Claim Construction Deadlines - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 2/20/2024 (ceg). (Entered: 02/16/2024) (3) |
| Feb 15, 2024 | 187 | SO ORDERED, re 186 Stipulation and Order to Extend Time for the parties to file a Joint Claim Construction Chart to February 16, 2024. Signed by Judge Jennifer L. Hall on 2/15/2024. (ceg) (Entered: 02/15/2024) (2) |
| Feb 14, 2024 | 186 | STIPULATION TO EXTEND TIME for the parties to file a Joint Claim Construction Chart to February 16, 2024 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 02/14/2024) (2) |
| Feb 12, 2024 | 185 | SO ORDERED, re 184 Stipulation and Order to Extend Time for the parties to file a Joint Claim Construction Chart to February 14, 2024. Signed by Judge Jennifer L. Hall on 2/12/2024. (ceg) (Entered: 02/12/2024) (2) |
| Feb 9, 2024 | 184 | STIPULATION TO EXTEND TIME for the parties to file a Joint Claim Construction Chart to February 14, 2024 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 02/09/2024) (2) |
| Feb 6, 2024 | 182 | STIPULATION TO EXTEND TIME for the parties to file a Joint Claim Construction Chart to February 9, 2024 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 02/06/2024) (2) |
| Feb 6, 2024 | 183 | SO ORDERED, re 182 Stipulation and Order to Extend Time for the parties to file a Joint Claim Construction Chart to February 9, 2024. Signed by Judge Jennifer L. Hall on 2/6/2024. (ceg) (Entered: 02/06/2024) (2) |
| Feb 5, 2024 | 181 | NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC's Reponses and Objections to Plaintiffs' First Set of Common Interrogatories (Nos. 1-12) filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) (Entered: 02/05/2024) (2) |
| Feb 1, 2024 | 179 | STIPULATION TO EXTEND TIME for the parties to file a Joint Claim Construction Chart to February 6, 2024 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 02/01/2024) (2) |
| Feb 1, 2024 | 180 | SO ORDERED, re 179 Stipulation and Order to Extend Time for the parties to file a Joint Claim Construction Chart to February 6, 2024. Signed by Judge Jennifer L. Hall on 2/1/2024. (ceg) (Entered: 02/01/2024) (2) |
| Jan 29, 2024 | 177 | SO ORDERED, granting 175 Stipulation of Dismissal between Plaintiffs and Defendant Alkem Laboratories Limited (*Party Alkem Laboratories Limited terminated). Signed by Judge Jennifer L. Hall on 1/29/2024. (ceg) (Entered: 01/29/2024) (4) |
| Jan 29, 2024 | 178 | SO ORDERED, granting 176 Stipulation of Dismissal between Plaintiffs and Defendant Sandoz Inc. (*Party Sandoz Inc. terminated). Signed by Judge Jennifer L. Hall on 1/29/2024. (ceg) (Entered: 01/29/2024) (4) |
| Jan 26, 2024 | 175 | STIPULATION of Dismissal (between Plaintiffs and Defendant Alkem Laboratories Limited) by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 1/26/2024 (ceg). (Entered: 01/26/2024) (4) |
| Jan 26, 2024 | 176 | STIPULATION of Dismissal (between Plaintiffs and Defendant Sandoz Inc.) by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 1/29/2024 (ceg). (Entered: 01/26/2024) (4) |
| Jan 12, 2024 | 174 | NOTICE OF SERVICE of Plaintiffs' Identification of Claim Terms and Phrases for Construction filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 01/12/2024) (9) |
| Jan 11, 2024 | 173 | NOTICE OF SERVICE of Defendants' Initial Proposed Claim Terms for Construction filed by Sun Pharmaceutical Industries Limited.(Wilson, Samantha) (Entered: 01/11/2024) (2) |
| Jan 5, 2024 | 172 | NOTICE OF SERVICE of Defendants' Initial Invalidity Contentions for U.S. Patent No. 11,542,239 filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 01/05/2024) (2) |
| Dec 22, 2023 | 171 | NOTICE OF SERVICE of Objections and Responses to Plaintiff's First Set of Common Interrogatories (Nos.1-12) and Plaintiff's First Set of Request for the Production of Documents and Things (Nos. 1-67) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 12/22/2023) (2) |
| Dec 21, 2023 | 169 | STIPULATION of Dismissal (between Plaintiffs and Lupin Defendants), by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 12/21/2023 (nms). (Entered: 12/21/2023) (4) |
| Dec 21, 2023 | 170 | SO ORDERED Granting 169 Stipulation and Proposed Order between Plaintiffs and Lupin Defendants (*Party Lupin Limited and Lupin Pharmaceuticals Inc. terminated). Signed by Judge Richard G. Andrews on 12/21/2023. (nms) (Entered: 12/21/2023) (4) |
| Dec 19, 2023 | 167 | NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-14); and (2) Plaintiffs' Objections and Responses to Defendants' First Set of Requests for Production to Plaintiffs (Nos. 1-107) filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 12/19/2023) (9) |
| Dec 19, 2023 | 168 | NOTICE OF SERVICE of 1) Defendant Sun Pharmaceutical Industries Limited's Answers to Plaintiffs' First Set of Interrogatories (Nos. 1-12); and 2) Defendant Sun Pharmaceutical Industries Limited's Responses to Plaintiffs' First Set of Requests for Production (Nos. 1-67) filed by Sun Pharmaceutical Industries Limited.(Wilson, Samantha) (Entered: 12/19/2023) (2) |
| Dec 18, 2023 | 165 | NOTICE OF SERVICE of Defendants Zenara Pharma Private Limited and Biophore India Pharmaceuticals Private Ltd.'s, (1) Highly Confidential Objections and Responses to Plaintiffs' First Set of Common Interrogatories (Nos. 1-12); and (2) Highly Confidential Objections and Responses to Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-67) filed by Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited.(Taylor, Daniel) (Entered: 12/18/2023) (2) |
| Dec 18, 2023 | 166 | NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC's Highly Confidential Reponses and Objections to Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-67) filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) (Entered: 12/18/2023) (2) |
| Dec 12, 2023 | 164 | STIPULATION and Proposed Order to Serve Initial Infringement Contentions for the '239 Patent to December 29, 2023 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. (Tigan, Jeremy) Modified on 12/12/2023 (lah). (Entered: 12/12/2023) (2) |
| Dec 1, 2023 | 163 | NOTICE OF SERVICE of (1) Plaintiffs' Initial Infringement Contentions Against Alkem Laboratories Limited for U.S. Patent No. 11,542,239; (2) Plaintiffs' Initial Infringement Contentions Against Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc. for U.S. Patent No. 11,542,239; (3) Plaintiffs' Initial Infringement Contentions Against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC for U.S. Patent Nos. 11,542,239, 10,537,572, and 10,682,351; (4) Plaintiffs' Initial Infringement Contentions Against Sun Pharmaceutical Industries Limited for U.S. Patent No. 11,542,239; and (5) Plaintiffs' Initial Infringement Contentions Against Zenara Pharma Private Limited and Biophore India Pharmaceuticals Private Ltd. for U.S. Patent No. 11,542,239 filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 12/01/2023) (7) |
| Nov 29, 2023 | 162 | STIPULATION and Proposed Order to Serve Initial Infringement Contentions for the '239 Patent to December 15, 2023 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 11/29/2023 (nms). (Entered: 11/29/2023) (2) |
| Nov 20, 2023 | 161 | NOTICE OF SERVICE of (1) Plaintiffs' First Set of Common Interrogatories (Nos. 1-12) to Defendants and (2) Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-67) to Defendants filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 11/20/2023) (9) |
| Nov 7, 2023 | 160 | NOTICE OF SERVICE of core technical documents bearing bates numbers SUNELGX00000001 - SUNELGX00007351 filed by Sun Pharmaceutical Industries Limited.(Wilson, Samantha) (Entered: 11/07/2023) (2) |
| Nov 3, 2023 | 158 | NOTICE OF SERVICE of core technical documents bearing Bates numbers LUPIN_ELAG0000001 - LUPIN_ELAG0032627 filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) (Entered: 11/03/2023) (2) |
| Nov 3, 2023 | 159 | NOTICE OF SERVICE of Defendants' Joint 1st Set of Interrogatories (Nos. 1-14) and Requests for Production (Nos. 1-107) filed by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited.(Taylor, Daniel) (Entered: 11/03/2023) (2) |
| Nov 2, 2023 | 156 | NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC's Core Technical Documents filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) (Entered: 11/02/2023) (2) |
| Nov 2, 2023 | 157 | NOTICE OF SERVICE of technical documents bates stamped HETERO-ORIL 000001-22946 filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 11/02/2023) (2) |
| Oct 30, 2023 | 155 | NOTICE OF SERVICE of 1) Sun Pharmaceutical Industries Ltd.'s Initial Disclosures Under Rule 26(a)(1) as to U.S. Patent No. 11,542,239; and 2) Sun Pharmaceutical Industries Ltd.'s Initial Disclosures Under Paragraph 3 of the Default Standard for Discover as to U.S. Patent No. 11,542,239 filed by Sun Pharmaceutical Industries Limited.(Wilson, Samantha) (Entered: 10/30/2023) (2) |
| Oct 27, 2023 | 148 | NOTICE OF SERVICE of Amended Rule 26(a)(1) Initial Disclosures and Amended Heteros Initial Paragraph 3 Disclosures filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 10/27/2023) (2) |
| Oct 27, 2023 | 149 | NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC's, (1) Initial Disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (2) Initial Disclosures concerning ESI pursuant to Paragraph 3 of the District of Delaware Default Standard for Discovery filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) (Entered: 10/27/2023) (2) |
| Oct 27, 2023 | 150 | ANSWER to 139 Answer to Complaint, Counterclaim by AbbVie Inc..(Tigan, Jeremy) (Entered: 10/27/2023) (6) |
| Oct 27, 2023 | 151 | NOTICE OF SERVICE of Defendant Alkem Laboratories Limited's, (1) Initial Disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (2) Initial Disclosures concerning ESI pursuant to Paragraph 3 of the District of Delaware Default Standard for Discovery filed by Alkem Laboratories Limited.(Taylor, Daniel) (Entered: 10/27/2023) (2) |
| Oct 27, 2023 | 152 | NOTICE OF SERVICE of Defendants Zenara Pharma Private Ltd. and Biophore India Pharmaceuticals Private Ltd.'s, (1) Initial Disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (2) Initial Disclosures concerning ESI pursuant to Paragraph 3 of the District of Delaware Default Standard for Discovery filed by Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited.(Taylor, Daniel) (Entered: 10/27/2023) (2) |
| Oct 27, 2023 | 153 | NOTICE OF SERVICE of (1) Defendant Lupin's Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); and (2) Defendant Lupin's Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) (Entered: 10/27/2023) (2) |
| Oct 27, 2023 | 154 | NOTICE OF SERVICE of (1) Plaintiffs' First Supplemental Fed. R. Civ. P. 26(a)(1) Initial Disclosures; and (2) Plaintiffs' First Supplemental Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery (directed to various defendants as outlined in notice) filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 10/27/2023) (9) |
| Oct 26, 2023 | 147 | NOTICE OF SERVICE of Defendants' Initial Invalidity Contentions filed by Sandoz Inc..(Gattuso, Dominick) (Entered: 10/26/2023) (2) |
| Oct 25, 2023 | 144 | SO ORDERED Granting 143 Stipulation and Proposed Order between Plaintiffs and MSN Defendants (*Party MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., and MSN Pharmaceuticals Inc. terminated). Signed by Judge Richard G. Andrews on 10/25/2023. (nms) (Entered: 10/25/2023) (4) |
| Oct 25, 2023 | 145 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,542,239 B2 . (Tigan, Jeremy) (Entered: 10/25/2023) (1) |
| Oct 25, 2023 | 146 | NOTICE OF SERVICE of Plaintiffs' First Supplemental Disclosures pursuant to Paragraph 4(a) of the Default Standard for Discovery (directed to various defendants as outlined in notice) filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 10/25/2023) (9) |
| Oct 24, 2023 | 143 | STIPULATION of Dismissal between Plaintiffs and MSN Defendants, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 10/24/2023 (nms). (Entered: 10/24/2023) (4) |
| Oct 19, 2023 | 142 | STIPULATION and [Proposed] Order Amending Case Schedule by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 10/19/2023) (5) |
| Oct 12, 2023 | 141 | STIPULATION and Proposed Order to Extend Time to file Initial Invalidity Contentions to October 19, 2023 and to move or respond to counterclaims to October 30, 2023 - filed by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited. (Taylor, Daniel) Modified on 10/13/2023 (nms). (Entered: 10/12/2023) (4) |
| Oct 10, 2023 | 138 | AMENDED ANSWER to 115 Amended Complaint, by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibits 1-17)(Taylor, Daniel) Modified on 10/10/2023 (nms). (Entered: 10/10/2023) (0) |
| Oct 10, 2023 | 139 | ANSWER to Complaint (filed in C.A. 23-cv-750-RGA), and COUNTERCLAIMS against AbbVie Inc., by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) Modified on 10/10/2023 (nms). (Entered: 10/10/2023) (28) |
| Oct 10, 2023 | 140 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Inc. for Lupin Pharmaceuticals Inc. filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) (Entered: 10/10/2023) (1) |
| Oct 5, 2023 | 137 | SO ORDERED Granting 136 Stipulation and Order of Dismissal between Plaintiffs and Defendant Teva Pharmaceuticals, Inc. regarding U.S. Patent No. 11, 542,239. Signed by Judge Richard G. Andrews on 10/5/2023. (nms) (Entered: 10/05/2023) (4) |
| Oct 4, 2023 | 132 | STIPULATION and Proposed Order, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 10/4/2023 (nms). (Entered: 10/04/2023) (4) |
| Oct 4, 2023 | 133 | SO ORDERED Granting 132 Stipulation and Proposed Order between Plaintiffs and Defendant Teva Pharmaceuticals, Inc. regarding U.S. Patents 10, 537,572, 10,682,351, and 11,344,551. Signed by Judge Richard G. Andrews on 10/4/2023. (nms) (Entered: 10/04/2023) (4) |
| Oct 4, 2023 | 134 | STIPULATION TO EXTEND TIME for Defendants to serve their initial Invalidity Contentions on Plaintiffs to October 12, 2023 - filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited. (Wilson, Samantha) (Entered: 10/04/2023) (4) |
| Oct 4, 2023 | 135 | STIPULATION Extending Time - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 10/5/2023 (nms). (Entered: 10/04/2023) (2) |
| Oct 4, 2023 | 136 | STIPULATION and Proposed Order of Dismissal between Plaintiff AbbVie Inc. and Defendant Teva Pharmaceuticals, Inc. regarding U.S. Patent No. 11,542,239, by AbbVie Inc.. (Tigan, Jeremy) Modified on 10/5/2023 (nms). (Entered: 10/04/2023) (4) |
| Oct 3, 2023 | 131 | AMENDED Answer to 115 Amended Complaint, and Separate Defenses, by Sun Pharmaceutical Industries Limited. (Attachments: # 1 Exhibits 1-19)(Gaza, Anne) Modified on 10/4/2023 (nms). (Entered: 10/03/2023) (0) |
| Oct 2, 2023 | 130 | STIPULATION and Proposed Order Extending Time to Amend Answer to Amended Complaint - filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Taylor, Daniel) Modified on 10/2/2023 (nms). (Entered: 10/02/2023) (2) |
| Sep 26, 2023 | 125 | STIPULATION Extending Time for to move or otherwise respond to Answer to Amended Complaint and Separate Defenses (D.I. 121) to October 3, 2023 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 9/26/2023 (nms). (Entered: 09/26/2023) (2) |
| Sep 26, 2023 | 126 | ANSWER to 119 Answer to Amended Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 9/26/2023 (nms). (Entered: 09/26/2023) (20) |
| Sep 26, 2023 | 127 | ANSWER to 120 Answer to Amended Complaint, and Counterclaim, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 9/26/2023 (nms). (Entered: 09/26/2023) (8) |
| Sep 26, 2023 | 128 | ANSWER to 122 Answer to Amended Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 9/26/2023 (nms). (Entered: 09/26/2023) (15) |
| Sep 26, 2023 | 129 | ANSWER to 123 Answer to Amended Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 9/26/2023 (nms). (Entered: 09/26/2023) (13) |
| Sep 20, 2023 | 124 | AMENDED Answer to 115 Amended Complaint, by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited. (Attachments: # 1 Exhibits 1-17)(Taylor, Daniel) Modified on 9/21/2023 (nms). (Entered: 09/20/2023) (0) |
| Sep 12, 2023 | 119 | ANSWER to 115 Amended Complaint, and COUNTERCLAIMS against AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc., by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V.(Grivner, Geoffrey) Modified on 9/12/2023 (nms). (Entered: 09/12/2023) (30) |
| Sep 12, 2023 | 120 | ANSWER to 115 Amended Complaint and COUNTERCLAIMS against AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc., by Teva Pharmaceuticals, Inc..(Keller, Karen) Modified on 9/12/2023 (nms). (Entered: 09/12/2023) (30) |
| Sep 12, 2023 | 121 | ANSWER to 115 Amended Complaint, by Sun Pharmaceutical Industries Limited.(Gaza, Anne) Modified on 9/12/2023 (nms). (Entered: 09/12/2023) (30) |
| Sep 12, 2023 | 122 | ANSWER to 115 Amended Complaint and COUNTERCLAIMS against All Plaintiffs, by MSN Pharmaceuticals Inc., MSN Life Sciences Pvt. Ltd., MSN Laboratories Private Ltd..(Gaza, Anne) Modified on 9/12/2023 (nms). (Entered: 09/12/2023) (30) |
| Sep 12, 2023 | 123 | ANSWER to 115 Amended Complaint and COUNTERCLAIMS against All Plaintiffs, by Sandoz Inc..(Gattuso, Dominick) Modified on 9/12/2023 (nms). (Entered: 09/12/2023) (30) |
| Sep 11, 2023 | 118 | ANSWER to 115 Amended Complaint, by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) Modified on 9/11/2023 (nms). (Entered: 09/11/2023) (30) |
| Sep 8, 2023 | 117 | MOTION for Pro Hac Vice Appearance of Attorney Patrick C. Keane - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Attachments: # 1 Certification of Patrick C. Keane, # 2 Text of Proposed Order)(Grivner, Geoffrey) (Entered: 09/08/2023) (0) |
| Aug 30, 2023 | 116 | ANSWER to 115 Amended Complaint, by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited.(Taylor, Daniel) Modified on 8/30/2023 (nms). (Entered: 08/30/2023) (30) |
| Aug 29, 2023 | 115 | Amended Complaint* (1) |
| Aug 16, 2023 | 114 | SO ORDERED Granting (D.I. 12 in 23-cv-374-RGA; D.I. 13 in 23-cv-607-RGA; D.I. 6 in 23-cv-750-RGA; D.I. 12 in 23-cv-448-RGA; D.I. 9 in 23-cv-684-RGA; D.I. 113 in 22-cv-1423-RGA-JLH; D.I. 13 in 23-cv-00470-RGA) Stipulation and Proposed Order Concerning Amended Complaint and Consolidation (see Order for further details). Signed by Judge Richard G. Andrews on 8/16/2023. Associated Cases: 1:22-cv-01423-RGA-JLH et al.(nms) (Entered: 08/16/2023) (7) |
| Aug 10, 2023 | 113 | STIPULATION and Proposed Order Concerning Amended Complaint and Consolidation, AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibits A-G, # 3 Supplemental ANDA form, # 4 Supplemental ANDA form, # 5 Supplemental ANDA form, # 6 Amended Patent Report, # 7 Exhibit 2)(Tigan, Jeremy) Modified on 8/10/2023 (nms). (Entered: 08/10/2023) (0) |
| Aug 8, 2023 | 112 | NOTICE of Change of Address for Deirdre M. Wells of Sterne, Kessler, Goldstein & Fox, P.L.L.C. by Teva Pharmaceuticals, Inc. (DiBenedetto, Emily) (Entered: 08/08/2023) (1) |
| Jul 13, 2023 | 111 | NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions (directed to various defendants as outlined in notice) filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 07/13/2023) (12) |
| Jun 1, 2023 | 110 | MOTION for Pro Hac Vice Appearance of Attorney Caroline L. Marsili - filed by Sun Pharmaceutical Industries Limited. (Wilson, Samantha) (Entered: 06/01/2023) (4) |
| May 26, 2023 | 108 | NOTICE OF SERVICE of Sun Pharmaceutical Industries Ltd.'s core technical documents filed by Sun Pharmaceutical Industries Limited.(Wilson, Samantha) (Entered: 05/26/2023) (2) |
| May 26, 2023 | 109 | NOTICE OF SERVICE of Defendants Lupin Limited's and Lupin Pharmaceuticals, Inc.'s Highly Confidential Core Technical Documents filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) (Entered: 05/26/2023) (3) |
| May 25, 2023 | 102 | NOTICE OF SERVICE of Defendant Alkem Laboratories Limited's Highly Confidential Core Technical Documents (Bates range ELGAKM0000001-19122) filed by Alkem Laboratories Limited.(Taylor, Daniel) (Entered: 05/25/2023) (2) |
| May 25, 2023 | 103 | NOTICE OF SERVICE of Defendants Zenara Pharma Private Ltd. and Biophore India Pharmaceuticals Private Ltd.'s Highly Confidential Core Technical Documents (Bates range ELGZEN0000001-38994) filed by Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited.(Taylor, Daniel) (Entered: 05/25/2023) (2) |
| May 25, 2023 | 104 | NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC's Highly Confidential Core Technical Documents (Bates range PRIN_ELAG00000001PRIN_ELAG00019507) filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) (Entered: 05/25/2023) (2) |
| May 25, 2023 | 105 | NOTICE OF SERVICE of Hetero's Highly Confidential Core Technical Documents filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 05/25/2023) (2) |
| May 25, 2023 | 106 | NOTICE OF SERVICE of Defendant Sandoz Inc.'s Core Technical Documents with a Bates range of SDZELX-000000001 through SDZELX-000017748 [HIGHLY CONFIDENTIAL] filed by Sandoz Inc..(Gattuso, Dominick) (Entered: 05/25/2023) (2) |
| May 25, 2023 | 107 | NOTICE OF SERVICE of MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., and MSN Pharmaceuticals Inc.'s core technical documents filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc..(Wilson, Samantha) (Entered: 05/25/2023) (2) |
| May 12, 2023 | 101 | SO ORDERED Granting 100 Stipulated Protective Order. Signed by Judge Richard G. Andrews on 5/12/2023. (nms) (Entered: 05/12/2023) (29) |
| May 11, 2023 | 100 | PROPOSED Stipulated Protective Order, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 5/12/2023 (nms). (Entered: 05/11/2023) (29) |
| May 8, 2023 | 99 | STIPULATION and Proposed Order to Extend Time to file a proposed protective order to May 11, 2023 - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) Modified on 5/9/2023 (nms). (Entered: 05/08/2023) (3) |
| May 4, 2023 | 98 | MOTION for Pro Hac Vice Appearance of Attorney Reinaldo Franqui Machin - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 05/04/2023) (8) |
| May 1, 2023 | 97 | STIPULATION and Proposed Order to extend time to file a proposed protective order to May 8, 2023 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 5/2/2023 (nms). (Entered: 05/01/2023) (3) |
| Apr 27, 2023 | 88 | NOTICE OF SERVICE of Plaintiffs' Disclosures to Defendant Alkem Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/27/2023) (3) |
| Apr 27, 2023 | 89 | NOTICE OF SERVICE of Plaintiffs' Disclosures to Hetero Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/27/2023) (3) |
| Apr 27, 2023 | 90 | NOTICE OF SERVICE of Plaintiffs' Disclosures to Lupin Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/27/2023) (3) |
| Apr 27, 2023 | 91 | NOTICE OF SERVICE of Plaintiffs' Disclosures to MSN Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/27/2023) (3) |
| Apr 27, 2023 | 92 | NOTICE OF SERVICE of Plaintiffs' Disclosures to Prinston Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/27/2023) (3) |
| Apr 27, 2023 | 93 | NOTICE OF SERVICE of Plaintiffs' Disclosures to Defendant Sandoz Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/27/2023) (3) |
| Apr 27, 2023 | 94 | NOTICE OF SERVICE of Plaintiffs' Disclosures to Defendant Sun Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/27/2023) (3) |
| Apr 27, 2023 | 95 | NOTICE OF SERVICE of Plaintiffs' Disclosures to Defendant Teva Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/27/2023) (3) |
| Apr 27, 2023 | 96 | NOTICE OF SERVICE of Plaintiffs' Disclosures to Zenara Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/27/2023) (3) |
| Apr 24, 2023 | 87 | STIPULATION and Proposed Order to extend time to file a proposed protective order to May 1, 2023 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 4/25/2023 (nms). (Entered: 04/24/2023) (3) |
| Apr 14, 2023 | 68 | NOTICE of Appearance by Daniel Taylor on behalf of Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zenara Pharma Private Limited, Zhejiang Huahai Pharmaceutical Co., Ltd. (Taylor, Daniel) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 69 | NOTICE OF SERVICE of 1) Sun Pharmaceutical Industries Ltd.'s Initial Disclosures Under Rule 26(a)(1), and 2) Sun Pharmaceutical Industries Ltd.'s Initial Disclosures Under Paragraph 3 of the Default Standard for Discovery filed by Sun Pharmaceutical Industries Limited.(Wilson, Samantha) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 70 | NOTICE OF SERVICE of Defendant Alkem Laboratories Limited's Fed. R. Civ. P. 26(a)(1)(A) Initial Disclosures & Paragraph 3 Disclosures filed by Alkem Laboratories Limited.(Taylor, Daniel) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 71 | NOTICE OF SERVICE of Defendants Zenara Pharma Private Ltd. and Biophore India Pharmaceuticals Private Ltd.'s Fed. R. Civ. P. 26(a)(1)(A) Initial Disclosures & Paragraph 3 Disclosures filed by Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited.(Taylor, Daniel) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 72 | NOTICE OF SERVICE of 1. Defendant Teva Pharmaceuticals, Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery 2. Defendant Teva Pharmaceuticals, Inc.'s Rule 26(a)(1) Initial Disclosures filed by Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 73 | NOTICE OF SERVICE of Initial Disclosures filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 74 | NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Alkem Defendant and (2) Plaintiffs' Initial Disclosures to Alkem Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 14, 2023 | 75 | NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Hetero Defendants and (2) Plaintiffs' Initial Disclosures to Hetero Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 14, 2023 | 76 | NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Lupin Defendants and (2) Plaintiffs' Initial Disclosures to Lupin Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 14, 2023 | 77 | NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to MSN Defendants and (2) Plaintiffs' Initial Disclosures to MSN Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 14, 2023 | 78 | NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Prinston Defendants and (2) Plaintiffs' Initial Disclosures to Prinston Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 14, 2023 | 79 | NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Sandoz Defendant and (2) Plaintiffs' Initial Disclosures to Sandoz Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 14, 2023 | 80 | NOTICE OF SERVICE of (i) Defendant Sandoz Inc.'s Disclosures Pursuant to Paragraph 3 of the District of Delaware Default Standard for Discovery; and, (ii) Defendant Sandoz Inc.'s Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Sandoz Inc..(Gattuso, Dominick) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 81 | NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Sun Defendant and (2) Plaintiffs' Initial Disclosures to Sun Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 14, 2023 | 82 | NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Teva Defendant and (2) Plaintiffs' Initial Disclosures to Teva Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 14, 2023 | 83 | NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Zenara Defendants and (2) Plaintiffs' Initial Disclosures to Zenara Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 14, 2023 | 84 | NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC's Fed. R. Civ. P. 26(a)(1)(A) Initial Disclosures and Paragraph 3 Disclosures filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 85 | NOTICE OF SERVICE of MSN Defendants' Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); and 2) MSN Defendants' Initial Disclosures Pursuant to Paragraph (3)(b)-(c) of the Default Standard for Discovery filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc..(Wilson, Samantha) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 86 | NOTICE OF SERVICE of (1) Defendants Lupin Limited and Lupin Pharmaceuticals, Inc's Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Plaintiffs; and (2) Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the District of Delaware's Default Standard for Discovery to Plaintiffs filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) (Entered: 04/14/2023) (3) |
| Apr 13, 2023 | 65 | MOTION for Pro Hac Vice Appearance of Attorney Christopher W. West - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) (Entered: 04/13/2023) (3) |
| Apr 13, 2023 | 66 | ORAL ORDER: The Motion for Pro Hac Vice Appearance (D.I. 65 ) is DISMISSED without prejudice to renew. Certifications by counsel need to be dated as to the day they were signed. Ordered by Judge Richard G. Andrews on 4/13/2023. (nms) (Entered: 04/13/2023) (0) |
| Apr 13, 2023 | 67 | MOTION for Pro Hac Vice Appearance of Attorney Christopher W. West - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) (Entered: 04/13/2023) (3) |
| Apr 12, 2023 | 64 | MOTION for Pro Hac Vice Appearance of Attorney Mitchell R. Williams - filed by Sun Pharmaceutical Industries Limited. (Wilson, Samantha) (Entered: 04/12/2023) (4) |
| Mar 21, 2023 | 60 | PROPOSED Scheduling Order, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Attachments: # 1 Letter)(Tigan, Jeremy) Modified on 3/21/2023 (nms). (Entered: 03/21/2023) (Main Document) (13) |
| Mar 21, 2023 | 61 | SCHEDULING ORDER: This matter will be referred to a magistrate judge to handle all discovery disputes including any that arise in connection with expert reports. Joinder of Parties due by 4/11/2024. Amended Pleadings due by 4/11/2024. Fact Discovery completed by 9/19/2024. Joint Claim Construction Brief due by 5/2/2024. A Markman Hearing is set for 6/3/2024, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 6/6/2025, at 9:00 AM in Courtroom 6A. A 3 day Bench Trial is set for 6/16/2025, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 3/21/2023. (nms) (Entered: 03/21/2023) (11) |
| Mar 21, 2023 | 62 | ORAL ORDER: The Rule 16(b) Conference scheduled for 3/23/2023, is CANCELED. Ordered by Judge Richard G. Andrews on 3/21/2023. (nms) (Entered: 03/21/2023) (0) |
| Mar 21, 2023 | 63 | ORAL ORDER: A Motion for Teleconference to Resolve Discovery Dispute should be filed if counsel finds they are unable to resolve a discovery matter. The suggested text for this motion can be found in Judge Hall's portion of the Court's website, in the "Forms" tab, under the heading "Motion for Teleconference to Resolve Discovery/Protective Order Disputes." The dispute will thereafter be addressed in accordance with Judge Hall's discovery dispute procedures. Ordered by Judge Jennifer L. Hall on 3/21/2023. (ceg) (Entered: 03/21/2023) (0) |
| Mar 21, 2023 | 60 | PROPOSED Scheduling Order, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Attachments: # 1 Letter)(Tigan, Jeremy) Modified on 3/21/2023 (nms). (Entered: 03/21/2023) (Letter to The Honorable Richard G. Andrews) (1) |
| Mar 20, 2023 | 58 | ANSWER to 50 Answer to Complaint and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 3/20/2023 (nms). (Entered: 03/20/2023) (17) |
| Mar 20, 2023 | 59 | MOTION for Pro Hac Vice Appearance of Attorney Deirdre M. Wells - filed by Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 03/20/2023) (3) |
| Mar 17, 2023 | 57 | NOTICE of Withdrawal of Appearance of Delaware Counsel, Eve Ormerod by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zenara Pharma Private Limited, Zhejiang Huahai Pharmaceutical Co., Ltd. (Ormerod, Eve) (Entered: 03/17/2023) (2) |
| Mar 8, 2023 | 56 | ANSWER to 46 Answer to Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 3/8/2023 (nms). (Entered: 03/08/2023) (12) |
| Mar 7, 2023 | 55 | Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 3/23/2023, at 9:00 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 3/7/2023. (nms) (Entered: 03/07/2023) (1) |
| Mar 3, 2023 | 53 | ANSWER to 44 Answer to Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 3/3/2023 (nms). (Entered: 03/03/2023) (7) |
| Mar 3, 2023 | 54 | ANSWER to 45 Answer to Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 3/3/2023 (nms). (Entered: 03/03/2023) (9) |
| Feb 28, 2023 | 52 | ANSWER to 1 Complaint, with Additional Defenses, by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited.(Belgam, Neal) Modified on 2/28/2023 (nms). (Entered: 02/28/2023) (30) |
| Feb 27, 2023 | 49 | ANSWER to 1 Complaint, and Affirmative Defenses, by Sun Pharmaceutical Industries Limited.(Gaza, Anne) Modified on 2/27/2023 (nms). (Entered: 02/27/2023) (30) |
| Feb 27, 2023 | 50 | ANSWER to 1 Complaint, and COUNTERCLAIMS against AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Grivner, Geoffrey) Modified on 2/27/2023 (nms). (Entered: 02/27/2023) (Main Document) (30) |
| Feb 27, 2023 | 51 | ANSWER to 43 Answer to Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 2/27/2023 (nms). (Entered: 02/27/2023) (13) |
| Feb 27, 2023 | 50 | ANSWER to 1 Complaint, and COUNTERCLAIMS against AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Grivner, Geoffrey) Modified on 2/27/2023 (nms). (Entered: 02/27/2023) (Exhibit 1) (30) |
| Feb 27, 2023 | 50 | ANSWER to 1 Complaint, and COUNTERCLAIMS against AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Grivner, Geoffrey) Modified on 2/27/2023 (nms). (Entered: 02/27/2023) (Exhibit 2) (30) |
| Feb 17, 2023 | 48 | MOTION for Pro Hac Vice Appearance of Attorney William A. Rakoczy - filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc.. (Wilson, Samantha) (Entered: 02/17/2023) (4) |
| Feb 15, 2023 | 46 | ANSWER to 1 Complaint, and COUNTERCLAIMS against all Plaintiffs, by MSN Pharmaceuticals Inc., MSN Life Sciences Pvt. Ltd., MSN Laboratories Private Ltd..(Gaza, Anne) Modified on 2/16/2023 (nms). (Entered: 02/15/2023) (30) |
| Feb 15, 2023 | 47 | MOTION for Pro Hac Vice Appearance of Attorney Kevin E. Warner, Matthew V. Anderson, Kevin P. Burke, and Adrianne C. Rose - filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc.. (Gaza, Anne) (Entered: 02/15/2023) (7) |
| Feb 10, 2023 | 44 | ANSWER to 1 Complaint, and COUNTERCLAIMS against AbbVie Inc., AbbVie Ltd., by Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) Modified on 2/13/2023 (nms). (Entered: 02/10/2023) (30) |
| Feb 10, 2023 | 45 | ANSWER to 1 Complaint, , COUNTERCLAIM against All Plaintiffs by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) (Entered: 02/10/2023) (30) |
| Feb 6, 2023 | 43 | ANSWER to 1 Complaint, and COUNTERCLAIMS against all Plaintiffs, by Sandoz Inc..(Gattuso, Dominick) Modified on 2/7/2023 (nms). (Entered: 02/06/2023) (30) |
| Feb 1, 2023 | 42 | MOTION for Pro Hac Vice Appearance of Attorney Emily L. Rapalino, Linnea P. Cipriano, Joshua S. Weinger, Louis L. Lobel, Kelly Grosshuesch and Cristina Denise Go of Goodwin Procter LLP - filed by Sandoz Inc.. (Gattuso, Dominick) (Entered: 02/01/2023) (9) |
| Jan 20, 2023 | 39 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Alkem Laboratories Limited. (Belgam, Neal) (Entered: 01/20/2023) (2) |
| Jan 20, 2023 | 40 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Biophore India Pharmaceuticals Private Ltd. for Zenara Pharma Private Limited filed by Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited. (Belgam, Neal) (Entered: 01/20/2023) (2) |
| Jan 20, 2023 | 41 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) (Entered: 01/20/2023) (1) |
| Jan 19, 2023 | 34 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Inc. for Lupin Pharmaceuticals Inc. filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) (Entered: 01/19/2023) (2) |
| Jan 19, 2023 | 35 | MOTION for Pro Hac Vice Appearance of Attorney Dmitry V. Shelhoff, Edward D. Pergament, Kenneth S. Canfield and Julia S. Kim - filed by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited. (Belgam, Neal) (Entered: 01/19/2023) (7) |
| Jan 19, 2023 | 36 | MOTION for Pro Hac Vice Appearance of Attorney Deepro R. Mukerjee, Lance A. Soderstrom, and Jillian M. Schurr - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) (Entered: 01/19/2023) (5) |
| Jan 19, 2023 | 37 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Sun Pharmaceutical Industries Limited. (Gaza, Anne) (Entered: 01/19/2023) (3) |
| Jan 19, 2023 | 38 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent MSN Laboratories Private Ltd. for MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc. filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc.. (Gaza, Anne) (Entered: 01/19/2023) (3) |
| Jan 18, 2023 | 31 | MOTION for Pro Hac Vice Appearance of Attorney Matthew Fedowitz, Andrew Cheslock and Grant Shackelford - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Attachments: # 1 Certification of Andrew R. Cheslock, # 2 Certification of Grant Shackelford, # 3 Certification of Matthew Fedowitz, # 4 Text of Proposed Order)(Grivner, Geoffrey) (Entered: 01/18/2023) (Main Document) (2) |
| Jan 18, 2023 | 32 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Hetero Drugs Limited, Corporate Parent Hetero Labs Limited for Hetero USA Inc. filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Grivner, Geoffrey) (Entered: 01/18/2023) (2) |
| Jan 18, 2023 | 33 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Sandoz Inc. filed by Sandoz Inc.. (Gattuso, Dominick) (Entered: 01/18/2023) (2) |
| Jan 18, 2023 | 31 | MOTION for Pro Hac Vice Appearance of Attorney Matthew Fedowitz, Andrew Cheslock and Grant Shackelford - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Attachments: # 1 Certification of Andrew R. Cheslock, # 2 Certification of Grant Shackelford, # 3 Certification of Matthew Fedowitz, # 4 Text of Proposed Order)(Grivner, Geoffrey) (Entered: 01/18/2023) (Certification of Andrew R. Cheslock) (2) |
| Jan 18, 2023 | 31 | MOTION for Pro Hac Vice Appearance of Attorney Matthew Fedowitz, Andrew Cheslock and Grant Shackelford - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Attachments: # 1 Certification of Andrew R. Cheslock, # 2 Certification of Grant Shackelford, # 3 Certification of Matthew Fedowitz, # 4 Text of Proposed Order)(Grivner, Geoffrey) (Entered: 01/18/2023) (Certification of Grant Shackelford) (2) |
| Jan 18, 2023 | 31 | MOTION for Pro Hac Vice Appearance of Attorney Matthew Fedowitz, Andrew Cheslock and Grant Shackelford - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Attachments: # 1 Certification of Andrew R. Cheslock, # 2 Certification of Grant Shackelford, # 3 Certification of Matthew Fedowitz, # 4 Text of Proposed Order)(Grivner, Geoffrey) (Entered: 01/18/2023) (Certification of Matthew Fedowitz) (2) |
| Jan 18, 2023 | 31 | MOTION for Pro Hac Vice Appearance of Attorney Matthew Fedowitz, Andrew Cheslock and Grant Shackelford - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Attachments: # 1 Certification of Andrew R. Cheslock, # 2 Certification of Grant Shackelford, # 3 Certification of Matthew Fedowitz, # 4 Text of Proposed Order)(Grivner, Geoffrey) (Entered: 01/18/2023) (Text of Proposed Order) (1) |
| Jan 17, 2023 | 30 | MOTION for Pro Hac Vice Appearance of Attorney H. Howard Wang & Jason A. Lief - filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Ormerod, Eve) (Entered: 01/17/2023) (5) |
| Jan 5, 2023 | 27 | STIPULATION and Proposed Order to answer, move, or otherwise respond to the Complaint to February 15, 2023 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 1/6/2023 (nms). (Entered: 01/05/2023) (3) |
| Jan 5, 2023 | 28 | ANSWER to 1 Complaint, with Additional Defenses, by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Ormerod, Eve) Modified on 1/5/2023 (nms). (Entered: 01/05/2023) (30) |
| Jan 5, 2023 | 29 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Zhejiang Huahai Pharmaceutical Co., Ltd. for Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd. filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Belgam, Neal) (Entered: 01/05/2023) (2) |
| Jan 4, 2023 | 25 | STIPULATION and Proposed Order - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 1/4/2023 (nms). (Entered: 01/04/2023) (2) |
| Jan 4, 2023 | 26 | STIPULATION and Proposed Order - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 1/4/2023 (nms). (Entered: 01/04/2023) (3) |
| Jan 3, 2023 | 22 | NOTICE OF SUBSTITUTION OF COUNSEL re Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.: Entry of appearance of attorney Geoffrey Graham Grivner. Attorney Kenneth Dorsney terminated. (Grivner, Geoffrey) (Entered: 01/03/2023) (2) |
| Jan 3, 2023 | 23 | STIPULATION and [Proposed] Order Regarding Teva Defendants - by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 01/03/2023) (5) |
| Jan 3, 2023 | 24 | SO ORDERED Granting 23 Stipulation and Proposed Order (*Party Teva Pharmaceutical Industries Ltd. terminated) (*Reset Answer Deadlines: Teva Pharmaceuticals, Inc. answer due 2/10/2023). Signed by Judge Richard G. Andrews on 1/3/2023. (nms) (Entered: 01/03/2023) (5) |
| Dec 21, 2022 | 21 | STIPULATION to Extend Time to Answer, Move, or otherwise Respond to the Complaint by February 27, 2023, by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Dorsney, Kenneth) Modified on 12/21/2022 (nms). (Entered: 12/21/2022) (2) |
| Dec 14, 2022 | 19 | STIPULATION and Proposed Order to answer, move, or otherwise respond to the Complaint - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 12/14/2022 (nms). (Entered: 12/14/2022) (3) |
| Dec 14, 2022 | 20 | STIPULATION and Proposed Order - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 12/14/2022 (nms). (Entered: 12/14/2022) (2) |
| Dec 5, 2022 | 18 | STIPULATION and Proposed Order to answer, move, or otherwise respond to the Complaint - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 12/5/2022 (nms). (Entered: 12/05/2022) (2) |
| Nov 28, 2022 | 17 | MOTION for Pro Hac Vice Appearance of Attorney Jennell C. Bilek and Samuel T. Lockner - filed by Sun Pharmaceutical Industries Limited. (Gaza, Anne) (Entered: 11/28/2022) (5) |
| Nov 15, 2022 | 16 | MOTION for Pro Hac Vice Appearance of Attorney Jennifer H. Roscetti, Danielle A. Duszczyszyn, William B. Raich, Constance P. Lee and Ryan V. McDonnell - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) (Entered: 11/15/2022) (8) |
| Nov 2, 2022 | 15 | NOTICE of Appearance by Karen Elizabeth Keller on behalf of Teva Pharmaceuticals, Inc. (Keller, Karen) (Entered: 11/02/2022) (1) |
| Oct 27, 2022 | 1 | Complaint* (1) |
| Oct 27, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 10/28/2022) (3) |
| Oct 27, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/27/2022. Date of Expiration of Patent: 09/01/2036. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 4 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/13/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 5 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/19/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 6 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/15/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 7 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/28/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 8 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/30/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 9 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/19/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 10 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/29/2022. Date of Expiration of Patent: 09/01/2036. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 11 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/13/2022. Date of Expiration of Patent: 09/01/2036. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 12 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,056,927 B2 ;7,176,211 B2 ;7,419,983 B2 ;10,537,572 B2 ;10,682,351 B2 ;11,344,551 B2. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 13 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AbbVie Inc. for AbbVie Ltd. filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (vfm) (Entered: 10/28/2022) (2) |
| Oct 27, 2022 | 14 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (vfm) (Entered: 10/28/2022) (2) |
